Zolpidem

Ivadal · Niotal · Edluar · CS-1159 · ZOLPIDEM · Zoipidem · SL-80.0750 · SL-80．0750-23N

Identifikatoren & physikalische Daten

CAS No.	82626-48-0
Summenformel	C19H21N3O
Durchschnittliche Molmasse	307,4 g/mol
Monoisotopische Masse	307,1684623 g/mol
SMILES	Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
InChIKey	ZAFYATHCZYHLPB-UHFFFAOYSA-N
PubChem CID	5732
ChEMBL	CHEMBL911
ChEBI	CHEBI:10125
EC No.	617-367-3
DTXSID	DTXSID7045946

Chemische & physikalische Eigenschaften

XLogP	2,5
Polarare Oberfläche (TPSA)	37,6
H-Brücken-Donoren	0
H-Brücken-Akzeptoren	2
Frei drehbare Bindungen	3
Schwere Atome	23
Formalladung	0
Komplexität	417
LogP (Verteilungskoeffizient)	3.02
Löslichkeit	2345% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.3 mg/mL<10mg/L(room temperature)
Schmelzpunkt	193-197196 °C189-191°C
Physical Description	Solid
Dissociation Constants	Strongest basic, 5.65
Kovats Retention Index	27882908.22797.52814.42756
Collision Cross Section	177.6 Å² [M+H]+ [CCS Type: DTMethod: single field calibrated]177.2 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
Dichte	1.12±0.1 g/cm3(Predicted)
Flammpunkt	9℃
Lagerbedingungen	Store at RT
Aggregatzustand	solid
pKa (Säurekonstante)	6.2(at 25℃)
Farbe	white
Hauptanwendungen	clinical testing
InChI	1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKey	ZAFYATHCZYHLPB-UHFFFAOYSA-N
SMILES	[n]21c(nc(c2CC(=O)N(C)C)c3ccc(cc3)C)ccc(c1)C
CAS Datenbank	82626-48-0(CAS DataBase Reference)
NIST chemische Informationen	Zolpidem(82626-48-0)

Sicherheit & Vorschriften

GHS-Einstufung	This chemical does not meet GHS hazard criteria for 10% (1 of 10) of reports.WarningH302 (90%): Harmful if swallowed [Warning Acute toxicity, oral]H336 (90%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H411 (90%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]P261, P264, P270, P271, P273, P301+P317, P304+P340, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 10 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 10 reports by companies.There are 2 notifications provided by 9 of 10 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Regulatorische Informationen	DEA schedule IV controlled substanceStatus: Active Update: 29-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/22051
Hazard Classes and Categories	Acute Tox. 4 (90%)STOT SE 3 (90%)Aquatic Chronic 2 (90%)
Treatment	General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be usefulhowever, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable. (L1712)

Anwendungen & Verwendung

Beschreibung

Zolpidem hemitamwe is a non-benzodiazepine hypnotic with specific agonist activity at type 1 benzodiazepine receptors, and is indicated for use in insomnia and other sleep disorders. Structurally zolpidem belongs to a chemically distinct class, thus lacking the side-effects and abuse potential of classical benzodiazepines. It is currently being studied as a pre-operative sedative.

Verwenden

A selective benzodiazepine receptor agonist not related chemically to benzodiazepines